Assembly Biosciences Q4 2025 Earnings Report

Assembly Biosciences EPS Results

• Actual EPS: $2.48
• Consensus EPS: -$0.51
• Beat/Miss: Beat by +$2.99
• One Year Ago EPS: N/A

Assembly Biosciences Revenue Results

• Actual Revenue: $42.47 million
• Expected Revenue: $7.42 million
• Beat/Miss: Beat by +$35.05 million
• YoY Revenue Growth: N/A

Assembly Biosciences Announcement Details

• Quarter: Q4 2025
• Date: 3/19/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Assembly Biosciences (NASDAQ:ASMB) (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle. Vebicorvir (ABI-H0731), a next-generation CpAM, is being studied in combination regimens to assess its ability to reduce surface antigen levels and achieve durable viral control. Assembly is also advancing ABI-H2158, an oral antiviral with broad potential to enhance host immune response and further suppress viral replication in chronic HBV patients.

Assembly conducts multi-center clinical trials across North America, Europe and Asia, collaborating with academic centers and global research networks to evaluate its candidates in diverse patient populations. The company operates its headquarters in Boulder, Colorado, with additional research activities in Cambridge, Massachusetts. Its management team brings extensive experience in antiviral drug development, leveraging prior success in hepatitis and oncology therapeutic programs.

Since its inception in 2015, Assembly has grown through strategic partnerships and in-licensing agreements, establishing a robust intellectual property portfolio around core modulation and prenylation inhibition. The company continues to engage regulatory authorities worldwide with the goal of delivering new, safe and effective treatment options for patients living with chronic HBV and HDV infections.